Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
The New York Proton Center
Eli Lilly and Company
Exscientia AI Limited
Conjupro Biotherapeutics, Inc.
Zumutor Biologics Inc.
PMV Pharmaceuticals, Inc
ViroMissile, Inc.
Duke University
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
IDEAYA Biosciences
Institut du Cancer de Montpellier - Val d'Aurelle
Daiichi Sankyo
Oscotec Inc.
Kidney Cancer Research Bureau
Second Life Therapeutics
Innate Pharma
Tanabe Pharma America, Inc.
RenJi Hospital
Cancer Research UK
NeoTX Therapeutics Ltd.
DualityBio Inc.
University of Colorado, Denver
Maastricht University Medical Center
Maastricht Radiation Oncology
Washington University School of Medicine
3B Pharmaceuticals GmbH
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
The Netherlands Cancer Institute
Brigham and Women's Hospital
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
NGM Biopharmaceuticals, Inc
OncoC4, Inc.
Columbia University
Theratechnologies
Elevation Oncology
Seagen Inc.
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
Poseida Therapeutics, Inc.
National Cancer Institute (NCI)